APR 06, 2016 07:30 AM PDT

Keynote Speaker: Recent Progress in Predictive Biomarker Testing in Oncology

C.E. CREDITS: P.A.C.E. CE
Speakers
  • Director of Molecular Pathology, Carolinas Pathology Group
    Biography
      After completing his undergraduate work in Applied Biology at Georgia Tech, John received his Ph.D. in Medical Genetics from the University of Alabama at Birmingham and his Doctorate in Medical Genetics at the Greenwood Genetic Center.
      Since 2001 he has worked with the Carolinas Pathology Group as Director of Molecular Pathology for the Carolinas Laboratory Network. His primary responsibility is supervision of the Molecular Pathology Laboratory which provides state of the art molecular testing services for the hospitals and facilities within the Carolinas HealthCare system.
      Dr Longshore is a diplomate of the American Board of Medical Genetics in Clinical Molecular Genetics and an active member of the American College of Medical Genetics, the American Society of Human Genetics and the Association for Molecular Pathology. Away from his professional life, John enjoys fly fishing, swimming, travel and spending time with his wife and children.

    Abstract:

    Recent advances in personalized medicine and associated companion diagnostic therapeutics have led to an increased utilization of genetic markers in oncology therapy selection.  The rapid acceleration of biomarker driven therapy has been widely accepted into clinical guidelines based upon proven clinical utility and unprecedented patient outcomes.  During this presentation, a discussion of processes used for tissue acquisition and processing, pre-analytics, biomarker testing, and result reporting will be presented.  A special emphasis will be given to the discussing the power and pitfalls of common biomarker testing techniques such as real-time PCR companion diagnostic testing, immunohistochemistry, FISH, and next-generation sequencing panels. The goal of this presentation is to help improve the oncology patient journey by increasing access to high quality biomarker testing.

    Learing Objectives:

    • To understand the fundamentals of personalized medicine and companion diagnostics
    • To review current therapeutic products associated with companion and complementary diagnostics
    • To gain an understanding of the future of personalized medicine in oncology

    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    Loading Comments...
    Show Resources